Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy

Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy

Bruton tyrosine kinase (BTK) inhibitors are the only FDA-approved treatments for Waldenström macroglobulinemia (WM). Factors prognostic of survival and predictive of response to BTK inhibitors remained to be clarified. We evaluated 319 patients with WM to identify predictive and prognostic factors...

Full description

Bibliographic Details
Main Authors: Branagan, A.R (Author), Castillo, J.J (Author), Flynn, C.A (Author), Guerrera, M.L (Author), Gustine, J.N (Author), Hunter, Z.R (Author), Kofides, A. (Author), Leventoff, C.R (Author), Liu, X. (Author), Meid, K. (Author), Munshi, M. (Author), Patterson, C.J (Author), Sarosiek, S.R (Author), Treon, S.P (Author), Tsakmaklis, N. (Author), White, T.P (Author)
Format: Article
Language:English
Published: American Society of Hematology 2022
Subjects:
adult
aged
Article
chemokine receptor CXCR4
cohort analysis
CXCR4 gene
drug response
female
gene mutation
human
human cell
ibrutinib
major clinical study
male
monotherapy
overall survival
progression free survival
retrospective study
risk factor
scoring system
Waldenstroem macroglobulinemia
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items